BioLife Solutions Ownership

BLFS Stock  USD 25.31  1.42  5.94%   
The majority of BioLife Solutions outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BioLife Solutions to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BioLife Solutions. Please pay attention to any change in the institutional holdings of BioLife Solutions as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
1988-09-30
Previous Quarter
47.8 M
Current Value
48.7 M
Avarage Shares Outstanding
10.6 M
Quarterly Volatility
14.3 M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLife Solutions. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
For more information on how to buy BioLife Stock please use our How to Invest in BioLife Solutions guide.

BioLife Stock Ownership Analysis

About 98.0% of the company shares are held by institutions such as insurance companies. The book value of BioLife Solutions was currently reported as 7.38. The company has Price/Earnings (P/E) ratio of 173.59. BioLife Solutions recorded a loss per share of 0.38. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people. For more info on BioLife Solutions please contact Michael Rice at 425 402 1400 or go to https://www.biolifesolutions.com.

BioLife Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as BioLife Solutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLife Solutions backward and forwards among themselves. BioLife Solutions' institutional investor refers to the entity that pools money to purchase BioLife Solutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2025-06-30
921.1 K
Palisade Capital Management Llc2025-06-30
919.5 K
Geneva Capital Management2025-06-30
901.8 K
Royal Bank Of Canada2025-06-30
791.3 K
Ing Investment Management Llc2025-06-30
720.1 K
Cramer Rosenthal Mcglynn Llc2025-06-30
704.2 K
Bank Of America Corp2025-06-30
671.7 K
Granahan Investment Management Inc..2025-06-30
643.2 K
Mutual Of America Capital Management Llc2025-06-30
638.4 K
Casdin Capital, Llc2025-06-30
7.7 M
Blackrock Inc2025-06-30
5.5 M
Note, although BioLife Solutions' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioLife Solutions Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Casdin Partners Master Fund, L.p. six days ago
Disposition of 1000000 shares by Casdin Partners Master Fund, L.p. of BioLife Solutions at 23.8 subject to Rule 16b-3
 
Aebersold Sarah over a week ago
Disposition of 217 shares by Aebersold Sarah of BioLife Solutions at 26.74 subject to Rule 16b-3
 
Duross Amy over two weeks ago
Disposition of 2000 shares by Duross Amy of BioLife Solutions at 24.6 subject to Rule 16b-3
 
Troy Wichterman over a month ago
Disposition of 30000 shares by Troy Wichterman of BioLife Solutions at 25.72 subject to Rule 16b-3
 
De Greef Roderick over a month ago
Disposition of 35417 shares by De Greef Roderick of BioLife Solutions at 26.15 subject to Rule 16b-3
 
De Greef Roderick over two months ago
Disposition of 37795 shares by De Greef Roderick of BioLife Solutions at 27.3 subject to Rule 16b-3
 
Sean Werner over two months ago
Disposition of 275 shares by Sean Werner of BioLife Solutions at 27.82 subject to Rule 16b-3
 
Aebersold Sarah over three months ago
Disposition of 714 shares by Aebersold Sarah of BioLife Solutions at 25.61 subject to Rule 16b-3
 
Sean Werner over three months ago
Disposition of tradable shares by Sean Werner of BioLife Solutions at 26.83 subject to Rule 16b-3
 
Todd Berard over three months ago
Disposition of 10000 shares by Todd Berard of BioLife Solutions at 25.53 subject to Rule 16b-3
 
Sean Werner over three months ago
Disposition of 1115 shares by Sean Werner of BioLife Solutions at 21.22 subject to Rule 16b-3
 
Todd Berard over six months ago
Disposition of 304 shares by Todd Berard of BioLife Solutions at 22.27 subject to Rule 16b-3

BioLife Solutions Outstanding Bonds

BioLife Solutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Solutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Solutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

BioLife Solutions Corporate Filings

F4
17th of December 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
17th of November 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of August 2025
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
10Q
7th of August 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for BioLife Stock Analysis

When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.